Ilan Yanuv

1.9k total citations
25 papers, 751 citations indexed

About

Ilan Yanuv is a scholar working on Endocrinology, Diabetes and Metabolism, Molecular Biology and Surgery. According to data from OpenAlex, Ilan Yanuv has authored 25 papers receiving a total of 751 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Endocrinology, Diabetes and Metabolism, 10 papers in Molecular Biology and 8 papers in Surgery. Recurrent topics in Ilan Yanuv's work include Diabetes Treatment and Management (21 papers), Metabolism, Diabetes, and Cancer (10 papers) and Pancreatic function and diabetes (7 papers). Ilan Yanuv is often cited by papers focused on Diabetes Treatment and Management (21 papers), Metabolism, Diabetes, and Cancer (10 papers) and Pancreatic function and diabetes (7 papers). Ilan Yanuv collaborates with scholars based in Israel, United States and Sweden. Ilan Yanuv's co-authors include Aliza Rozenberg, Ofri Mosenzon, Deepak L. Bhatt, Avivit Cahn, Itamar Raz, Itamar Raz, Boaz Hirshberg, Benjamin M. Scirica, Christina Stahre and Cheryl Wei and has published in prestigious journals such as Diabetes Care, Diabetes and Journal of the American Society of Nephrology.

In The Last Decade

Ilan Yanuv

23 papers receiving 730 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ilan Yanuv Israel 13 663 265 206 108 88 25 751
Aliza Rozenberg Israel 13 663 1.0× 266 1.0× 206 1.0× 108 1.0× 89 1.0× 26 753
Markus F. Scheerer Germany 19 543 0.8× 290 1.1× 197 1.0× 66 0.6× 62 0.7× 38 753
Zin Zin Htike United Kingdom 10 804 1.2× 283 1.1× 365 1.8× 44 0.4× 44 0.5× 14 924
Tomio Jinnouchi Japan 15 363 0.5× 161 0.6× 145 0.7× 56 0.5× 59 0.7× 38 591
Claire C. J. Dekkers Netherlands 9 599 0.9× 319 1.2× 210 1.0× 228 2.1× 21 0.2× 13 734
S. Petrykiv Netherlands 6 415 0.6× 211 0.8× 162 0.8× 225 2.1× 28 0.3× 27 533
Ludwig Merker Germany 10 1.3k 2.0× 719 2.7× 525 2.5× 79 0.7× 156 1.8× 30 1.4k
Jan Marquard Germany 14 662 1.0× 422 1.6× 114 0.6× 21 0.2× 229 2.6× 30 806
S. Durán‐García Spain 11 978 1.5× 441 1.7× 497 2.4× 45 0.4× 28 0.3× 20 1.1k
Christina Stahre Sweden 9 414 0.6× 151 0.6× 174 0.8× 103 1.0× 14 0.2× 12 524

Countries citing papers authored by Ilan Yanuv

Since Specialization
Citations

This map shows the geographic impact of Ilan Yanuv's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ilan Yanuv with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ilan Yanuv more than expected).

Fields of papers citing papers by Ilan Yanuv

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ilan Yanuv. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ilan Yanuv. The network helps show where Ilan Yanuv may publish in the future.

Co-authorship network of co-authors of Ilan Yanuv

This figure shows the co-authorship network connecting the top 25 collaborators of Ilan Yanuv. A scholar is included among the top collaborators of Ilan Yanuv based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ilan Yanuv. Ilan Yanuv is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Cohen, Cheli Melzer, Meir Schechter, Aliza Rozenberg, et al.. (2023). Long-Term, Real-World Kidney Outcomes with SGLT2i versus DPP4i in Type 2 Diabetes without Cardiovascular or Kidney Disease. Clinical Journal of the American Society of Nephrology. 18(9). 1153–1162. 11 indexed citations
4.
Wainstein, Julio, Maya Ish‐Shalom, Tali Ganz, et al.. (2023). Curalin supplement for patients with type 2 diabetes mellitus. Diabetes/Metabolism Research and Reviews. 39(4). e3624–e3624.
5.
Schechter, Meir, Stephen D. Wiviott, Itamar Raz, et al.. (2023). Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial. The Lancet Diabetes & Endocrinology. 11(4). 233–241. 15 indexed citations
6.
Schechter, Meir, Cheli Melzer Cohen, Aliza Rozenberg, et al.. (2023). Kidney function loss and albuminuria progression with GLP-1 receptor agonists versus basal insulin in patients with type 2 diabetes: real-world evidence. Cardiovascular Diabetology. 22(1). 126–126. 12 indexed citations
7.
Schechter, Meir, Cheli Melzer Cohen, Ilan Yanuv, et al.. (2022). Epidemiology of the diabetes-cardio-renal spectrum: a cross-sectional report of 1.4 million adults. Cardiovascular Diabetology. 21(1). 104–104. 16 indexed citations
8.
Cahn, Avivit, Stephen D. Wiviott, Ofri Mosenzon, et al.. (2022). Association of Baseline HbA1c With Cardiovascular and Renal Outcomes: Analyses From DECLARE-TIMI 58. Diabetes Care. 45(4). 938–946. 26 indexed citations
9.
Schechter, Meir, Ilan Yanuv, Aliza Rozenberg, et al.. (2022). Medical cannabis for pain management in patients undergoing chronic hemodialysis: randomized, double-blind, cross-over, feasibility study. Clinical Kidney Journal. 16(4). 701–710. 2 indexed citations
10.
Schechter, Meir, Cheli Melzer Cohen, Aliza Rozenberg, et al.. (2021). Cardiorenal outcomes with sodium/glucose cotransporter-2 inhibitors in patients with type 2 diabetes and low kidney risk: real world evidence. Cardiovascular Diabetology. 20(1). 169–169. 17 indexed citations
11.
Cahn, Avivit, Stephen D. Wiviott, Ofri Mosenzon, et al.. (2020). 1101-P: Cardiorenal Outcomes with Dapagliflozin by Baseline Glucose Lowering Agents: Analyses from DECLARE-TIMI 58. Diabetes. 69(Supplement_1). 3 indexed citations
12.
Mosenzon, Ofri, Stephen D. Wiviott, Hiddo J.L. Heerspink, et al.. (2020). Effect of Dapagliflozin on Risk for Fast Decline in eGFR: Analysis from DECLARE-TIMI 58 Trial. Journal of the American Society of Nephrology. 31(10S). 345–346. 1 indexed citations
13.
Raz, Itamar, Stephen D. Wiviott, Hiddo J.L. Heerspink, et al.. (2020). 303-OR: Effect of Dapagliflozin on Risk for Fast Decline in EGFR: Analyses from the DECLARE-TIMI 58 Trial. Diabetes. 69(Supplement_1). 1 indexed citations
14.
Bajaj, Harpreet S., Itamar Raz, Ofri Mosenzon, et al.. (2020). Cardiovascular and renal benefits of dapagliflozin in patients with short and long‐standing type 2 diabetes: Analysis from the DECLARE‐TIMI 58 trial. Diabetes Obesity and Metabolism. 22(7). 1122–1131. 21 indexed citations
15.
16.
Yaron, Marianna, Zohar Landau, Tali Ganz, et al.. (2019). Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes. Diabetes Care. 42(7). 1178–1184. 153 indexed citations
17.
Cahn, Avivit, Ofri Mosenzon, Deepak L. Bhatt, et al.. (2017). Hypoglycaemia manifestations and recurrent events: L essons from the SAVOR‐TIMI 53 outcome study. Diabetes Obesity and Metabolism. 19(7). 1045–1050. 5 indexed citations
18.
Mosenzon, Ofri, Gil Leibowitz, Deepak L. Bhatt, et al.. (2016). Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. Diabetes Care. 40(1). 69–76. 202 indexed citations
19.
Cahn, Avivit, Itamar Raz, Ofri Mosenzon, et al.. (2016). Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. Diabetes Care. 39(8). 1329–1337. 9 indexed citations
20.
Mosenzon, Ofri, Cheryl Wei, Jaime A. Davidson, et al.. (2015). Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial. Diabetes Care. 38(11). 2142–2150. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aliza Rozenberg Breakdown of academic impact, for papers by Markus F. Scheerer Breakdown of academic impact, for papers by Zin Zin Htike Breakdown of academic impact, for papers by Tomio Jinnouchi Breakdown of academic impact, for papers by Claire C. J. Dekkers Breakdown of academic impact, for papers by S. Petrykiv Breakdown of academic impact, for papers by Ludwig Merker Breakdown of academic impact, for papers by Jan Marquard Breakdown of academic impact, for papers by S. Durán‐García Breakdown of academic impact, for papers by Christina Stahre
Rankless by CCL
2026